Cytiva to Manufacture Covid Vaccine Supplies Under HHS Contract

Oct. 13, 2020, 7:46 PM

Massachusetts-based Cytiva will expand its manufacturing capacity for products essential to producing Covid-19 vaccines under an agreement announced Tuesday by the Department of Health and Human Services.

The agreement with Cytiva is the latest to increase manufacturing capacity in the U.S. to aid in developing and administering Covid-19 vaccines and therapeutics. The Trump administration has been struggling since the start of the pandemic to fill supply shortages.

To date, the federal government has provided more than $1.1 billion to purchase needles, syringes, vials, and supply kits, and to expand the capacity to manufacture these ancillary supplies for Covid-19 vaccines and ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.